secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAMED PHARMACEUTICALS INC. (ORMP)
CIK:        0001176309
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001213900-22-071607
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Oramed licenses oral insulin (ORMD-0801) to Medicox for South Korea; up to $18M milestones plus 15% royalties
--------------------------------------------------------------------------------

- Exclusive 10-year license for ORMD-0801 in South Korea.
- Up to $18M in developmental milestones; $2M already received.
- Up to 15% royalties on gross sales; Medicox funds regulatory approval.
- Medicox also pays transfer price per capsule; distribution targets agreed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1176309/000121390022071607/0001213900-22-071607-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1176309/000121390022071607/ea168587-8k_oramed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-071607

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer